Skip to Main Content

Paper Details

Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
Kidney Cancer
31
2017
BAP1, BAP1 mutation, BAP1 mutations, Clear, Clear Cell Renal Cell Carcinoma, KDM5C, PBRM1, Patients, SETD2, TERT, TERT mutations, TERT promoter, VEGF, VHL, ccRCC, ccRCC tumors, clear cell renal cell carcinoma, metastatic, metastatic cc RCC, metastatic ccRCC, non, patients, tumors
Author NameAffiliation
Marc LadanyiMemorial Sloan Kettering Cancer Center
William LeeMemorial Sloan Kettering Cancer Center
Abraham Ari HakimiMemorial Sloan Kettering Cancer Center
James J HsiehMemorial Sloan Kettering Cancer Center
James J HsiehMemorial Sloan Kettering Cancer Center
James J HsiehMemorial Sloan Kettering Cancer Center
James J HsiehMemorial Sloan Kettering Cancer Center
  • 1 - 7

Datasets

Release 1.2